Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventions in the process of NASH/fibrosis. We investigated the representation of molecular disease patterns characteristic for human NASH in high‐fat diet (HFD)‐fed Ldlr‐/‐.Leiden mice and studied the effects of obeticholic acid (OCA) on these disease profiles. Multiplatform serum metabolomic profiles and genome‐wide liver transcriptome from HFD‐fed Ldlr‐/‐.Leiden mice were compared with those of NASH patients. Mice were profiled at the stage of mild (24 weeks HFD) and severe (34 weeks HFD) fibrosis, and after OCA intervention (24‐34 weeks; 10 mg/kg/day). Effects of OCA were analyzed histologically, biochemically, by immunohistochemistry, using deuterated water technology (de novo collagen formation), and by its effect on the human‐based transcriptomics and metabolomics signatures. The transcriptomics and metabolomics profile of Ldlr‐/‐.Leiden mice largely reflected the molecular signature of NASH patients. OCA modulated the expression of these molecular profiles and quenched specific proinflammatory‐profibrotic pathways. OCA attenuated specific facets of cellular inflammation in liver (F4/80‐positive cells) and reduced crown‐like structures in adipose tissue. OCA reduced de novo collagen formation and attenuated further progression of liver fibrosis, but did not reduce fibrosis below the level before intervention. Conclusion: HFD‐fed Ldlr‐/‐.Leiden mice recapitulate molecular transcriptomic and metabolomic profiles of NASH patients, and these signatures are modulated by OCA. Intervention with OCA in developing fibrosis reduces collagen deposition and de novo synthesis but does not resolve already manifest fibrosis in the period studied. These data show that human molecular signatures can be used to evaluate the translational character of preclinical models for NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 3×
“In line with the observations in the FLINT trial,(16) we observed an improvement in hepatic fibrosis after OCA treatment in the present study.”
BackgroundResultMudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“(1) The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) is one of the most promising candidate drugs, based on preclinical studies in acute models of inflammation and fibrosis(13,14) as well as on published results from clinical studies.(15,16) However, the mechanisms by which OCA can attenuate metabolically…”
BackgroundNonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i19.2300 · Cited by 554 · cited 1×
“(43) Models with nonobese phenotypes such as methionine-choline deficient diet feeding, STZ treatment, or Pten deficiency(44) are typically more rapid, extreme, and liver-centric, and run the risk of underestimating the contributions of other organs.”
BackgroundMetabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Self-citationVerbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236
Cited by
Gart, E., Souto Lima, E., Schuren, F., De Ruiter, C. G. F., Attema, J., Verschuren, L., Keijer, J., Salic, K., Morrison, M. C., & Kleemann, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010001 · Cited by 1,093
Self-citationA Microphysiological System for Studying Nonalcoholic Steatohepatitis
Kostrzewski, T., Maraver, P., Ouro‐Gnao, L., Levi, A., Snow, S., Miedzik, A., Rombouts, K., & Hughes, D. (2020) · Hepatology Communications · doi:10.1002/hep4.1450 · Cited by 77
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology · doi:10.1002/hep.32427 · Cited by 65
Self-citationMASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
“In a phase IIa trial including individuals with hepatic steatosis and fibrosis, treatment for 12 weeks with a FAS inhibitor, TVB-2640, dose-dependently decreased circulating ALT, AST and liver fat determined by MRI-PDFF.”
BackgroundInfluential
Metadata
- Authors
- Morrison, M. C., Verschuren, L., Salic, K., Verheij, J., Menke, A., Wielinga, P. Y., Iruarrizaga‐Lejarreta, M., Gole, L., Yu, W., Turner, S., Caspers, M. P. M., Martínez‐Arranz, I., Pieterman, E., Stoop, R., van Koppen, A., van den Hoek, A. M., Mato, J. M., Hanemaaijer, R., Alonso, C., & Kleemann, R.
- Venue
- Hepatology Communications
- Published
- 2018-10-29
- Volume
- 2
- Issue
- 12
- Pages
- 1513-1532
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2899024699
- Cited by
- 58
- References
- 16
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice. https://app.cochat.ai/papers/10.1002/hep4.1270
- The paper
- Morrison, M. C., Verschuren, L., Salic, K., Verheij, J., Menke, A., Wielinga, P. Y., Iruarrizaga‐Lejarreta, M., Gole, L., Yu, W., Turner, S., Caspers, M. P. M., Martínez‐Arranz, I., Pieterman, E., Stoop, R., van Koppen, A., van den Hoek, A. M., Mato, J. M., Hanemaaijer, R., Alonso, C., & Kleemann, R. (2018). Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice. Hepatology Communications. https://doi.org/10.1002/hep4.1270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.